VIDEO: New advancements in mantle cell lymphoma treatment

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

For mantle cell lymphoma this is a difficult to treat disease that has a sort of relentless pattern of relapse. And so we always need new therapies. The recent advances probably the biggest two would be the introduction of the oral B T K inhibitors for mammal-cell-lymphoma which has been, you know, now approved for several years. We have three different B T K inhibitors ibrutinib, acalabrutinib, and zanubrutinib. And, and these are very active and very effective for mantle-cell-lymphoma with high response rates and durations of response ranging in the kind of two to three year range. So they're very good and, and less toxic and better than most prior chemotherapy drugs but they're not a solution to mantle cell lymphoma or a cure. And so the, the other major advance over the past couple years has really been the introduction of CAR T-cell therapy. So right now we have one FDA approved product Brex CAPTA G Notel, which is anti CD 19 CAR T-cell therapy. And it's very effective, very high response rates high complete remission rates, even in patients who've been previously treated with oral B T K inhibitors. So I would say right now for, for relapsed mantle cell that's really been the major two steps forward in the past several years.